This article is more than 5 years old. Information may no longer be current.

SeaSpine announces launch of transforaminal lumbar interbody fusion device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SeaSpine Holdings Corporation announced the full commercial launch of its Hollywood VI NanoMetalene transforaminal lumbar interbody fusion device.

According to a company press release, the device is commercially available and is indicated for spinal fusion surgeries at one or two contiguous levels from L2-S1 in skeletally mature patients with degenerative disc disease. The Hollywood VI NanoMetalene device is reportedly good for placement in the anterior column of the spine and has a fully coated graft aperture for autogenous bone graft for fusion.

“Surgeon response to our NanoMetalene family of implants has been overwhelmingly positive — in part because this technology offers the best features of titanium and [polyetheretherketone] PEEK in an interbody solution that we believe supports bone growth,” Keith Valentine, chief executive officer of SeaSpine, said in the release. “We will continue to expand our NanoMetalene offering throughout 2016 and into 2017 to ensure this differentiated technology is available for all interbody spine procedures.”

Reference:

www.seaspine.com